Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

PHASE3UnknownINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 30, 2011

Primary Completion Date

October 31, 2013

Study Completion Date

March 31, 2014

Conditions
Chronic Kidney Disease
Interventions
OTHER

Diet counseling

If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).

OTHER

Diet counseling

If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).

DRUG

Phosphorus binder

If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.

Trial Locations (1)

24153

RECRUITING

VA Medical Center, Salem

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Shire

INDUSTRY

lead

Salem Veterans Affairs Medical Center

FED

NCT01357317 - Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction | Biotech Hunter | Biotech Hunter